key: cord-0805300-umqwkhuc
authors: Ahmed, Sakir; Handa, Rohini
title: Management of Connective Tissue Disease–related Interstitial Lung Disease
date: 2022-05-03
journal: Curr Pulmonol Rep
DOI: 10.1007/s13665-022-00290-w
sha: 3e0520c9c06f405b1eb2ecdbe8a508a8ff8d7314
doc_id: 805300
cord_uid: umqwkhuc

PURPOSE OF REVIEW: This review aims to collate current evidence on the screening, diagnosis, and treatment of various connective tissue disease (CTD)–associated interstitial lung diseases (CTD-ILD) and present a contemporary framework for the management of such patients. It also seeks to summarize treatment outcomes including efficacy and safety of immunosuppressants, anti-fibrotics, and stem cell transplantation in CTD-ILD. RECENT FINDINGS: Screening for ILD has been augmented by the use of artificial intelligence, ultra-low dose computerized tomography (CT) of the chest, and the use of chest ultrasound. Serum biomarkers have not found their way into clinical practice as yet. Identifying patients who need treatment and choosing the appropriate therapy is important to minimize the risk of therapy-related toxicity. The first-line drugs for systemic sclerosis (SSc) ILD include mycophenolate and cyclophosphamide. Nintedanib, an anti-fibrotic tyrosine kinase inhibitor, is approved for use in SSc-ILD. The US Food and Drug Administration (FDA) has recently approved tocilizumab subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with SSc-ILD. Autologous stem cell transplantation may have a role in select cases of SSc-ILD. SUMMARY: CTD-ILD is a challenging area with diverse entities and variable outcomes. High-resolution CT is the investigative modality of choice. Treatment decisions need to be individualized and are based on patient symptoms, lung function, radiologic abnormalities, and the risk of disease progression. Precision medicine may play an important role in determining the optimal therapy for an individual patient in the future.

Interstitial lung disease (ILD) occurring in a person with a known or classifiable connective tissue disease (CTD) is termed CTD-ILD. Approximately 15% of ILDs will have a background CTD [1] . Very often presence of ILD is the major determinant of mortality in a patient with a CTD [2••] . In systemic sclerosis (SSc), around 30% have symptomatic ILD and this is associated with 10-year mortality of 40% [3, 4] . For rheumatoid arthritis, severe interstitial lung disease is often reported in 2-8% while active case finding estimates are around 8-80% [5-7••] . In mixed connective tissue disease (MCTD), around 50% have ILD on CT imaging [8] . Again, in idiopathic inflammatory myositis (IIM) cohorts, there is a wide variation in the prevalence of ILD from 20 to 78% depending on the methods used to define ILD [9] .

At times, a patient may have an ILD with some features of CTDs such as Raynaud or ANA (anti-nuclear antibody) positivity but not meet the criteria for any CTD. Previously, different names have been proposed for such entities such as lung dominant CTD [10] . However, with the description of the criteria for interstitial pneumonia with autoimmune This article is part of the Topical Collection on Interstitial Lung Disease features (IPAF), this term is now widely used in the literature [11••] .

The emergence of the concept of IPAF stems from the recognition that the presence of autoimmune features predicts response to treatment, and hence, favourable prognosis [12] . Thus, clinical significance is attached to the differentiation of CTD-ILD and IPAF from idiopathic pulmonary fibrosis (IPF). IPF to CTD-ILD appears to be a continuous spectrum bridged by IPAF [13] . The component of autoimmunity is most prominent CTD-ILD, lesser in IPAF and minimal in IPF. This implies that immunosuppressant therapies have better outcomes in CTD-ILD than in IPAF, and possibly are harmful in IPF [14] .

The last decade has seen a sea change in the concept of treatment of CTD-ILD from stem cell transplantation for systemic sclerosis (SSc)-ILD to the change in the dogma of avoiding methotrexate in CTD-ILD [3, 15] . Also, of the antifibrotic agents for IPF, nintedanib has shown promise even in CTD-ILD [16••] . The precipitous arrival of the COVID-19 has shown that the presence of ILD is an additional risk factor necessitating rational use of immunosuppressants in such patients [17] .

A literature search was made on Scopus and MEDLINE/ Pubmed with search terms "connective tissue disorder" or equivalent terms, "interstitial lung disease" or equivalent terms; "interstitial pneumonia with autoimmune features" and "management" or "treatment." The search was restricted to the last 3 years. The bibliography of selected articles was also scanned for additional relevant articles. The authors have focussed on recent articles but have included older articles also if they have particular relevance to current treatment strategies as per recommendations for a biomedical review [18] .

There is a central role of lung epithelial damage in the pathogenesis of CTD-ILD. Genetic factors associated with SSc-ILD include HLA-DRB1 alleles, DQB1*05, interferon regulatory factor 5 (IRF5), signal transducer and activator of transcription 4 (STAT4), CD226 (DNAX accessory molecule 1), NLR family, pyrin domain containing 1 (NLRP1), interleukin-1 receptor-associated kinase-1 (IRAK1), connective tissue growth factor (CTGF), and T-cell surface glycoprotein zeta chain (CD3ζ) or CD247 [19] . The MUC5B promoter region polymorphisms have been associated with ILD at large, and also with RA-ILD [20] .

In rheumatoid lung disease, the same mucosal pathological factors associated with precipitation of arthritis such as smoking or air pollutants and microbiota may also contribute to the genesis of bronchial epithelial injury [21] . Transforming growth factor-β (TGF-β), endothelin-1, and platelet-derived growth factor (PDGF) are major players in the pathogenesis of fibrosis in the setting of SSc. These lead to an endothelial mesenchymal transition (EMT) of the epithelial cell that predisposes to fibroblasts converting to myofibroblasts and leading to fibrosis [22] . The role of autoantibodies has been proposed but not fully established [23] .

Elucidating the pathogenesis enables the evolution of targeted therapies [24] . The initial trials targeting TGF-β or its receptors met with mixed success [25, 26] . This might have been due to the pleiotropic effects of TGF-β as well as various redundant canonical and non-canonical downstream pathways. However, exploring the role of interleukin-6(IL-6) has led to good results with the IL-6 receptor antagonist tocilizumab. The use of subcutaneous tocilizumab led to both improvement of the modified Rodnan skin score and stabilization of functional vital capacity (FVC) [27••] . Similarly, interleukin-17 and PD-1 (programmed cell death protein1) have a role in SSc-mediated fibrosis [28] . Since there are clinically available molecules that can target these, these might be tried in the context of future clinical trials.

The diagnosis of CTD-ILDs is clinico-radiologic supported by the demonstration of autoantibodies. Plain chest radiographs are insensitive. The gold standard for ILD detection is high-resolution CT (HRCT) and very early disease may be better picked up on prone imaging.

The differential diagnosis of CTD-ILD and most important distinguishing features are summarized in Table 1 .

HRCT is employed for diagnosis and follow-up. All CTD-ILDs do not progress. Especially in RA-ILD, 20-60% of individuals have some "interstitial lung abnormality (ILA)" of which only 35-45% progress. Sub-pleural distributions and higher total volume of ILAs are associated with progression [29••] . Therefore, it is important to find out the radiological extent and other biomarkers of progression before treating all ILAs. Quantitative CTs have the advantage of being able to quantify progression and can detect changes even before experienced radiologists [30••] .

There are concerns regarding repeating CT scans for monitoring or screening due to radiation exposure. Thus, lowdose CT for screening has been developed and validated in CTD-ILD [31] . Ultra-low dose CTs have been used for other lung diseases and with the advent of artificial intelligence (AI) in radiology, it may become viable for CTD-ILD too [32] . Current quantitative CT (qCT) parameters can quantify lung involvement in SSc and differentiate it from IPF [33] .

Radiological deterioration mirrors functional deterioration and hence, it has been suggested to perform biannual CT scans to document disease progression [34] . The use of ultra-low-dose and AI-based quantitative CTs may make this possible in the recent future without any increased radiation risks to patients.

In the last decade, ultrasound has come up as a screening tool for ILD in CTD [35, 36] . It can also be used for prognostication. In SSc, the presence of more than 5 B-lines is associated with worsening ILD [37] . Despite its limitations, it detects sub-pleural disease that has a higher risk of progression. Moreover, it is inexpensive, less timeconsuming, and widely available in rheumatology clinics where musculoskeletal ultrasound is practiced. Coupled with pulmonary function tests, it can be a valuable screening tool to screen for the need for a CT. Another upcoming modality is high-strength MRI that is non-ionizing and has also been shown to detect CTD-ILD [38] .

Out of various serum biomarkers proposed in the context of CTD-ILD, the strongest evidence is for SP-D (surfactant protein), KL-6 (Krebs von den Lungen-6), and CCL19 in SSc-ILD [39••] . KL-6 is a well-known biomarker for ILD in general. CCL19 can predict SSc-ILD progression [39••] . Even the tumour markers CA (carbohydrate antigen)-125 and CA19-9 have been studied as markers of epithelial damage and can predict short-term mortality [40] . Similarly, in RA-ILD, CA125, CA19-9, CEA (carcinoembryonic antigen), and KL-6 have been validated as biomarkers [41] . Other biomarkers for RA-ILD can include genetic polymorphisms of the MUC5B gene and serum interleukin-13 levels [20, 42] . Due to comparatively low sensitivity and specificity, serum biomarkers have not broken the cost-benefit barrier for commercial use.

Since HRCT of the thorax provides fairly detailed information of lung structure and pathology [43] , a lung biopsy is rarely required in the diagnosis or management of CTD-ILD. Mediastinal lymphadenopathy, ankle arthritis, eye or skin manifestations may be seen Chronic eosinophilic pneumonia Idiopathic eosinophilic lung disease; characterized by nonsegmental airspace consolidations with peripheral predominance Chronic (many months to years) Pneumoconiosis

Occupational lung diseases -history of exposure will be present Amyloidosis

Other manifestations: joints, kidneys, or skin Other ILD/idiopathic interstitial fibrosis Absence of CTD-ILD or IPAF defining features When ILD develops in the setting of an established CTD and the diagnosis is straight forward, lung biopsy is not warranted. It may be useful in instances like suspected sarcoidosis where transbronchial biopsy may be utilized. Biopsy may be required to rule out more airway-centric complications such as bronchiolitis, hypersensitivity pneumonitis, sarcoidosis, or malignancy [44] . Lung tissue can be obtained via transbronchial biopsy (TBLB), transbronchial cryobiopsy (cryo-TBB), bronchoscopic ultrasound-guided biopsy, or video-assisted thoracoscopic surgery (VATS). Thus, open surgical lung biopsy via thoracotomy is rarely recommended in the setting of an ILD [45] .

There are limited trials on CTD-ILD as a whole. Most of the evidence is derived from the trial conducted in SSc-ILD patients. Also, there is some emerging data on the treatment of RA-ILD and myositis-associated ILD. However, the most challenging part is often to determine the risk-benefit ratio of different therapies for individual patients.

The OMERACT (outcome measures in rheumatic diseases) defines clinically meaningful progression of CTD-ILD as ≥ 10% relative decline in forced vital capacity (FVC) or ≥ 5% to < 10% relative decline in FVC and ≥ 15% relative decline in DLCO [46••] . Often, especially if the patient has no or minimal symptoms, it is appropriate to document clinically relevant progression of CTD-ILD before initiating treatment. Other than such decline in the PFT or the presence of symptomatic disease, a decision to treat could be made if the visually estimated volume of interstitial abnormalities is more than 20% of the total lung volume on imaging (CT) or the absolute FVC is less than 70%. The PaO2/ FiO2 ratio is one of the strongest individual parameters to predict survival in CTD-ILD [47] .

In RA-ILD, the presence of usual interstitial pneumonia (UIP) pattern with subpleural reticulation, traction bronchiectasis, and honeycombing usually is a harbinger of progressive disease [48] . Of these, the presence of honeycombing, regardless of the underlying pattern, has the strongest association with poor prognosis [49] .

In SSc, the most active part of the disease is the first 4-5 years and the bulk of clinical trials include patients in these initial years only [7••] . Similarly, in most other CTDs, there is a perception that the longer the ILD has been present, the less likely it is to progress. Thus, there is limited logic or even evidence to treat CTD-ILDs beyond the initial 7-8 years of onset or detection.

The European consensus statements on CTD-ILD provide a framework of reference for monitoring patients and making a decision on treatment initiation or escalation [50 •] . The essence of these guidelines is summarized in Table 2 .

Corticosteroid use will depend on the underlying CTD and extra-pulmonary manifestations. In most cases of SSc, corticosteroids are avoided as the possible harms outweigh the benefit [51] . In cases of MCTD-ILD and RA-ILD, there is adequate justification from the underlying disease to use appropriate (low to moderate) doses of steroids. Prednisolone 0.5 mg/kg body weight/day is used as the usual starting Speed of progression and disease severity should drive decisions for escalation Hemopoietic stem-cell transplantation and lung transplants are effective in specific subsets of SSc-ILD dose with a gradual taper over weeks to months depending on clinical response. Steroids are the standard of care for inflammatory myositis-associated ILD. Higher doses (1 mg/ kg body weight/day of prednisolone) may be required at time of treatment initiation. In cases of IPAF, steroids may be considered depending on the autoimmune features present and the morphology of the ILD. Lymphocytic interstitial pneumonia and non-specific interstitial pneumonia (NSIP) have better response to corticosteroids than usual interstitial pneumonia (UIP) [45] . The dose and duration need to be individualized. Caution is warranted as the use of corticosteroids in IPF is associated with increased mortality [52] . Table 3 .

The most important evidence come from the SLS (scleroderma lung studies) I and II [53••, 54••]. SLS I established the role of oral CYC for SSc-ILD. Oral CYC is often more toxic than monthly intravenous pulse CYC. Thus, the authors are more comfortable using pulse CYC for SSc-ILD. The SLS II showed the non-inferiority of MMF to CYC in the management of SSc-ILD. The number of death in the CYC arm was numerically more in SLS II. Though the difference was not statistically significant, the study was not powered to look at this. Thus, some authors make a case of first use of MMF in SSc-ILD and then to shift to CYC in case of MMF failure.

The SENSCIS trial [57••] is noteworthy for showing the benefit of nintedanib for CTD-ILD. However, if the fine print is read, unlike other trials where the relative decline of FVC was measured, in the SENSCIS trial, only absolute change in FVC was statistically different between the drug and placebo groups. Thus, until more data emerges, it may be prudent to take it with a pinch of salt.

Interestingly, the two common drugs used in the clinic for SSc-ILD, CYC, and MMF have not received approval of the US Food and Drug Administration (FDA) while nintedanib and tocilizumab have been approved [63] .

Rituximab (RTX) is another drug that is used for SSc-ILD if refractory to CYC and MMF. It has not been explored in the context of a formal RCT. There is extensive real-world data on its use documented in the EUSTAR registry [64] and this has been validated with systematic reviews [65] .

However, a recent prospective observation nested in the EUSTAR cohort showed only improvements in the skin but not in lung function with RTX [39••] . Thus, until more clear evidence is available, it may be appropriate to use RTX only after the failure of both MMF and CYC. Table 4 summarizes the immunosuppressants that are the standard of care for different CTD-ILDs. The choice of a particular agent is governed by several factors (Fig. 1) . The duration of therapy is debatable since evidence of long-term use is not available. Most trials have been for 6-24 months, and that is the basis of the recommendation of therapies in the short term [54••, 63] . In the experience of the authors, azathioprine may be a good option for long-term maintenance in both SSc-ILD and RA-ILD. This is especially true after cyclophosphamide therapy, the use of which is recommended for 6 months.

Evidence for CTD-ILDs other than SSc-ILD is limited to non-RCT studies only. The most important change in practice is the use of methotrexate (MTX) in RA-ILD. The evidence is quite clear that MTX protects from RA-ILD progression and does not exacerbate it as once thought [66, 67] . There is some evidence that anti-TNF (tumour necrosis factor) therapies may improve small airway disease in RA-ILD [68] .

Myositis-ILD is in itself a heterogeneous entity with a myriad of clinical phenotypes and autoantibodies present. First-line drugs are often methotrexate and azathioprine but calcineurin inhibitors (cyclosporine and tacrolimus) and rituximab are gradually becoming more popular [69] . Some rapidly progressing phenotypes may require aggressive therapies. The rapidly progressing MDA-5 antibody phenotype has been treated with high-dose steroids with at least two of cyclophosphamide, tofacitinib, and rituximab [70 ••] . The JAK inhibitor tofacitinib may be useful in refractory cases [71] while other salvage therapies are rituximab and plasma exchange [72] .

For rapidly progressing patients with SSc-ILD without pulmonary hypertension, autologous haematopoietic stem cell transplant (AHSCT) has a definite role in the management. Despite many patients not meeting these criteria, it is a major step forward in therapeutics. Within the last decade, two trials [73, 74] have set the tone for exploring this avenue further (Table 5 ). These two trials and the preceding phasetwo trial have shown that careful patient selection is required for optimal outcomes. The SCOT (Scleroderma: Cyclophosphamide or Transplantation) study was ended before the scheduled time because the interim analysis showed a clear benefit in the transplant arm [74••] . Beyond the controlled trials, there is also evidence for AHSCT from transplant registries [76, 77] . In the registry data, mortality was around 6% mostly attributable to cardiac and cyclophosphamide toxicity [77] .

A multi-disciplinary effort is required in CTD-ILD [78] . There are a host of non-pharmacological therapies SSc-ILD Mycophenolate 2-3 g daily orally Pulse CYC doses are associated with lesser toxicity but most trials have used daily oral doses Rituximab (2 g induction as given below) and tocilizumab (162 mg subcutaneous weekly) are second-line agents Cyclophosphamide Oral: 2-3 mg/kg body weight/day Pulse: 600/m 2 iv every month For a maximum of 6 months Nintedanib may be added to either of the above at 150 mg 12 hourly orally RA-ILD Rituximab 1 g intravenous infusion 2 weeks apart Methotrexate and leflunomide may have a role especially in early minimally symptomatic disease A proportion of RA-ILD do not progress or progress very slowly even without treatment Azathioprine 2-3 mg/kg body weight/day orally Cyclophosphamide (as mentioned above) Mycophenolate 2-3 g daily orally Myositis-ILD High doses steroid (1 mg/kg body weight of prednisolone) with one of the following: Rituximab 1 g 2 weeks apart (Or 375 mg/m 2 body surface area weekly × 4 weeks)

Rapidly progressing disease: Pulse steroids with one or two of the following: Rituximab, cyclophosphamide, tofacitinib, or intravenous immunoglobulin Mycophenolate 2-3 g daily orally Azathioprine 2-3 mg/kg body weight/day Cyclophosphamide (as mentioned above) Fig. 1 Deciding on who and how to treat to supplement management, specially in patients with advanced disease.

All patients with CTD-ILD should be vaccinated with adult vaccines recommended for persons having chronic lung diseases [79] . The basic vaccines include influenza and pneumococcal vaccines [80] . Often vaccination in persons with lung diseases is less than ideal [81] . Both patient-focussed and clinician-focussed activities are required to increase vaccination coverage in susceptible people with CTD-ILD [82] .

Pulmonary rehabilitation includes exercise training, education, and behaviour change [83] . Patients must be advised to stop smoking. Physical activity and exercise training can improve both functional status and quality of life [84] . Pulmonary rehabilitation has been shown to benefit in stable ILD regardless of disease severity [85] .

It is often the comorbidities that lead to added susceptibility to infections including COVID-19 [17] . Sometimes the dyspnoea attributed to the ILD may be actually due to pulmonary hypertension or associated myositis or cardiac disease due to the underlying CTD. Thus, these must be adequately addressed. Sarcopenia is common in symptomatic ILD and should be corrected with proper diet and physical activity [86] .

At end-stage fibrosis with dyspnoea at rest, there is an unmet need for adequate palliative care [87] . This includes effective pharmacological and psychosocial interventions to ease daily functioning. Palliative care should not be restricted only to end-of-life situations. Social isolation and lack of communication due to persistent dyspnoea can be challenging problems [88] . Oxygen therapy has shown to improve exercise capacity but has limited effects on dyspnoea [89 ••] . Long-term oxygen therapy is a standard of care for resting hypoxemia and ambulatory oxygen may help exertional hypoxemia [90] . There exist guidelines for effective home oxygen therapy that may be utilized for CTD-ILD [91] .

Lung transplantation may be considered for endstage CTD-ILD. In the presence of severe pulmonary [93] . In the case of SSc-ILD also, the rate of graft survival mirrors those of IPF.

Various therapies have been tried in the context of phase 1/2 trials for SSc including inebilizumab (anti-CD19), dabigatran, Wnt signaling blocker C-82, pomalidomide (antiangiogenic and immunomodulator of lymphocytes and myelocytes), rilonacept (IL-1 receptor analog), romilkimab (bispecific antibody against IL-4 and IL-13), lenabasum (type 2 cannabinoid receptor agonist), abatacept (co-stimulation blocker), belimumab (anti-BAFF, B cell-activating factor), riociguat (soluble guanylate cyclase stimulator), and lanifibranor (PPAR agonist) [94] . A phase II study of abituzumab in SSc-ILD was terminated due to very low recruitment [95] . The various RCTs registered in clinical trials for CTD-ILDs are summarized in Table 6 .

The main challenge facing the treating clinician is disease heterogeneity as different diseases underlie CTD-ILD. Even for the same sub-group with a similar autoantibody profile, the clinical progression and response to treatment vary. Immunosuppression needs to be balanced with the risk of infections that are not uncommon in these patients and may even be fatal. The future lies in personalized precision medicine [96] . Beyond the recognition of clinical phenotypes, a combined multi-omics (genetic, methylomics, transcriptomics, and proteomics) approach is expected to classify patients into rapid progressors, slow progressors, or very slow progressors. This will help guide the timing of therapy and hopefully predict response to different drug groups enabling the clinician to choose the optimum combination of immunosuppressants, anti-fibrotics, and immune re-booting procedures such as autologous haematopoietic stem cell transplantation.

We have not considered sarcoidosis and vasculitis-associated ILD under the umbrella of CTD-ILD. There are case series and observational data for many more therapies in different CTD-ILDs. However, we have focussed only on therapies with robust evidence by way of controlled trials or registry data.

The heterogeneity of CTD-ILDs and the limited, but expanding, evidence make the task of the clinician exciting yet challenging at the same time. The advent of novel therapeutic agents with the application of biomarkers to stratify patients is a work in progress.

This is a review of published literature and does not require ethics clearance.

Conflict of Interest SA has received honorarium as speaker from Pfizer, Dr Reddy's, Cipla and Novartis (unrelated to the current work). RH has served as speaker, consultant, advisory board member for Abbott India, Pfizer, IPCA, Janssen, Eli Lilly, Novartis (unrelated to the current work).

No conflict of interest pertaining to this work.

This article does not contain any studies with human or animal subjects performed by any of the authors.

particular interest, published recently, have been highlighted as: •• Of major importance

Treatment of connective tissue diseaseassociated interstitial lung disease: the pulmonologist's point of view

Highlights the recent changes in the dogma of CTD-ILD management

Systemic sclerosis-associated interstitial lung disease

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Annals of the Rheumatic Diseases

Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers

Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease

Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement

Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications

Significance of connective tissue diseases features in pulmonary fibrosis

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features

Prospective nationwide multicentre cohort study of the clinical significance of autoimmune features in idiopathic interstitial pneumonias

Interstitial pneumonia with autoimmune features (IPAF)

Idiopathic Pulmonary Fibrosis Clinical Research Network

Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebocontrolled, parallel-group trial

Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic

Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors

Genetic predictors of systemic sclerosisassociated interstitial lung disease: a review of recent literature

MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease

Mechanisms of lung disease development in rheumatoid arthritis

Interstitial lung disease in systemic sclerosis: insights into pathogenesis and evolving therapies

A Closer Look at the Role of Anti-CCP Antibodies in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and bronchiectasis

Systemic sclerosis: from pathogenesis to targeted therapy

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

Interleukin-17 pathways in systemic sclerosis-associated fibrosis

Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management

The extent and diverse trajectories of longitudinal changes in rheumatoid arthritis interstitial lung diseases using quantitative HRCT scores

Feasibility of low-dose CT with spectral shaping and third-generation iterative reconstruction in evaluating interstitial lung diseases associated with connective tissue disease: an intra-individual comparison study

Ultralow-dose chest computed tomography for interstitial lung disease using model-based iterative reconstruction with or without the lung setting

Association of quantitative computed tomography ındices with lung function and extent of pulmonary fibrosis in patients with systemic sclerosis

Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests

The use of ultrasound for assessing interstitial lung involvement in connective tissue diseases

The predictive role of lung ultrasound in progression of scleroderma interstitial lung disease

Prognostic value of lung ultrasound B-lines in systemic sclerosis

Novel imaging approaches in systemic sclerosis-associated interstitial lung disease

Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population

Identification of serum interleukin-13 and interleukin-13 receptor subunit expressions: rheumatoid arthritis-associated interstitial lung disease

Computed tomography of chronic diffuse infiltrative lung disease. Part 1

Interstitial lung disease evaluation: detecting connective tissue disease

Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society

Connective tissue disease-associated interstitial lung diseases (CTD-ILD) -report from OMERACT CTD-ILD Working Group

Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study

Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)

Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology Elsevier

Corticosteroids and the risk of scleroderma renal crisis: a systematic review

Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department

Cyclophosphamide versus placebo in scleroderma lung disease

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis

2021;101671. Comprehensive review of anti-fibrotic therapies in SSc as a whole

Nintedanib for systemic sclerosis-associated interstitial lung disease

A multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial

Tocilizumab in systemic sclerosis: a randomised, doubleblind, placebo-controlled, phase 3 trial

Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial

Efficacy and safety of pirfenidone in systemic sclerosisrelated interstitial lung disease-a randomised controlled trial

Systemic sclerosis-associated interstitial lung disease: how to incorporate two Food and Drug Administration-approved therapies in clinical practice. Arthritis Rheumatol

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis

Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts

Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature

Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment

Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis

Tofacitinib for refractory interstitial lung diseases in antimelanoma differentiation-associated 5 gene antibody-positive dermatomyositis

Management of myositis-associated interstitial lung disease

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

Myeloablative autologous stem-cell transplantation for severe scleroderma

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

Management issues in rheumatoid arthritis-associated interstitial lung disease

Cost-effectiveness of adult vaccinations: a systematic review

Pneumococcal vaccination and chronic respiratory diseases

Use of Pneumococcal and influenza vaccine in patients with COPD, asthma bronchiale and interstitial lung diseases in south east Germany

Interventions to increase the rate of influenza and pneumococcal vaccination in patients with chronic obstructive pulmonary disease: a scoping review

Current best practice in rehabilitation in interstitial lung disease

The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial

Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation?

Body composition, muscle function, and physical performance in fibrotic interstitial lung disease: a prospective cohort study

Palliative care in interstitial lung disease: living well

Palliative care for people with non-malignant lung disease: summary of current evidence and future direction

Oxygen therapy for interstitial lung disease: a systematic review

Oxygen for interstitial lung diseases

Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline

Lung transplantation: indications and contraindications

Survival and outcomes after lung transplantation for connective tissue disease-associated interstitial lung diseases

An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years

STRATUS: a phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease

Prospects for stratified and precision medicine in systemic sclerosis treatment

Disclaimer All views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any institution or association.